G1 Therapeutics to Participate in the 40th Annual J.P. Morgan and H.C. Wainwright BioConnect Virtual Conferences in January 2022

Rhea-AI Summary

G1 Therapeutics (Nasdaq: GTHX), an oncology-focused biopharmaceutical company, announces participation in two virtual investor conferences in January 2022. CEO Jack Bailey and CMO Raj Malik will engage in a fireside chat at the H.C. Wainwright BioConnect 2022 conference on January 10 at 7:00 AM EST. Bailey will present on January 12 at 1:30 PM EST during the 40th Annual J.P. Morgan Healthcare Conference. Webcasts for both events will be available on the company's website.

RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences in January.

• G1’s Chief Executive Officer Jack Bailey and Chief Medical Officer Raj Malik, M.D. will participate in a fireside chat during the H.C. Wainwright BioConnect 2022 conference. The webcast of the fireside chat will become available at 7:00 AM EST on January 10, 2022.

• On January 12, 2022, at 1:30 PM EST, Mr. Bailey will provide a corporate presentation during the 40th Annual J.P. Morgan Healthcare Conference.
  

The webcast of both events will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.

About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating trilaciclib in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contacts:
Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
wroberts@g1therapeutics.com

FAQ

What events is G1 Therapeutics participating in January 2022?

G1 Therapeutics will participate in the H.C. Wainwright BioConnect 2022 conference on January 10 and the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022.

Who will represent G1 Therapeutics at the H.C. Wainwright conference?

CEO Jack Bailey and CMO Raj Malik will represent G1 Therapeutics during the fireside chat at the H.C. Wainwright BioConnect conference.

What time will G1 Therapeutics' presentation take place at the J.P. Morgan conference?

G1 Therapeutics' presentation by CEO Jack Bailey is scheduled for January 12, 2022, at 1:30 PM EST.

How can I access the webcasts for G1 Therapeutics' presentations?

The webcasts for G1 Therapeutics' presentations will be accessible on the company's Events & Presentations page on their website.

What is G1 Therapeutics focused on developing?

G1 Therapeutics is focused on developing next-generation therapies for cancer, including their product COSELA™.